LIP
BMY icon

Liontrust Investment Partners’s Bristol-Myers Squibb BMY Stock Holding History

Liontrust Investment Partners’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,200
Closed -$426K – 211
2021
Q3 		$426K Buy
+7,200
New +$474K 0.01% 220
2020
Q4 		$627K Buy
+10,100
New +$621K 0.01% 204

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Liontrust Investment Partners's BMY Position: Q4 2021 in Review

Liontrust Investment Partners sold out of Bristol-Myers Squibb (BMY) in Q4 2021, closing a stake of 7,200 shares — an estimated $426K sold.

Liontrust Investment Partners first reported a position in BMY in Q4 2020 and held it in 2 quarters. The position peaked at $627K in Q4 2020. 2,444 funds tracked by Wall St. Rank hold BMY as of Q4 2021.

  • Liontrust Investment Partners reported no remaining Bristol-Myers Squibb position as of Q4 2021 after selling out during the quarter.
  • Liontrust Investment Partners sold 7,200 Bristol-Myers Squibb shares in Q4 2021, an estimated $426K.
  • Liontrust Investment Partners first reported a position in Bristol-Myers Squibb in Q4 2020 and held it in 2 quarters.
  • Liontrust Investment Partners's Bristol-Myers Squibb position peaked at $627K in Q4 2020.
  • 2,444 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2021.

Based on Liontrust Investment Partners's 13F filing for Q4 2021, filed 26 Jan 2022.